difenoxin

Trade name: Motofen

Small moleculeapproved

Approved

Jul 14, 1978

Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R) is a brand mixture which combines atropine sulfate and difenoxin hydrochloride. It is approved by the FDA to treat acute and chronic diarrhea. Difenoxin is an active metabolite of the anti-diarrheal drug, diphenoxylate, which is also used in combination with atropine in the brand mixture Lomotil(R). It works mostly in the periphery and activates opioid receptors in the intestine rather than the central nervous system (CNS). Difenoxin is also closely related to loperamide, but unlike loperamide it is still capable of crossing the blood brain barrier to produce weak sedative and analgesic effects. However, the antidiarrheal potency of difenoxin is much greater than its CNS effects, which makes it an attractive alternative to other opioids. Motofen(R) is a combination of atropine, an anticholinergic drug, and difenoxin, an antidiarrheal drug. It has been used in many countries for many years as a second line opioid-agonist antidiarrheal, which exists an intermediate between loperamide and paragoric. Diarrhea which is a result of cyclic or diarrhea predominant Inflammatory Bowel Syndrome may not be treated effectively with difenoxin, diphenoxylate, or loperamide. As such, diarrhea and cramping which does not respond to non-centrally acting derivatives or belladonna derivatives such as atropine are often treated with conservative doses of codeine. In patients with acute ulcerative colitis, as induction of toxic megacolon is possible, and thus use of Motofen(R) is cautioned. Motofen(R) has been assigned pregnancy category C by the FDA, and is to be used only when the potential benefits outweigh the potential risk to the fetus. The safety of use during lactation is unknown and thus not recommended. Each five-sided dye free MOTOFEN® tablet contains: 1 mg of difenoxin (equivalent to 1.09 mg of difenoxin hydrochloride) and 0.025 mg of atropine sulfate (equivalent to 0.01 mg of atropine). Difenoxin acts as an antidiarrheal by activating peripheral opioid receptors in the small intestine and thereby inhibiting peristalsis. However, research has suggested that non-opioid receptor pathways exist. This would explain the potent antidiarrheal effects of difenoxin despite only limited opioid action. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 2 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1970s

  1. Jul 14, 1978

    Sebela Pharmaceuticals — Earliest FDA Approval

  2. Jul 14, 1978

    Sebela Pharmaceuticals — NDA Secondary Org

  3. Jul 14, 1978

    LEGACY PHARMA — NDA Secondary Org

  4. Jul 14, 1978

    Sebela Pharmaceuticals — NDA Organization

Indications

Mechanism of action

Combination products

  • motofen

    with atropine

    Also known as motofen half-strength

Approval history

  • approvedJul 14, 1978

Chemistry & pharmacology

Loading structure…

SMILES

N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1
Mol. weight
424.54 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotic acid
  • 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotic acid
  • difenoxilic acid
  • difenoxin
  • difenoxin
  • difenoxin
  • difenoxin
  • difenoxin
  • difenoxin
  • difenoxin
  • difenoxin
  • difenoxin
  • difenoxina
  • difenoxina
  • difenoxine
  • difenoxin hcl
  • difenoxin hcl
  • difenoxin hcl
  • difenoxin hydrochloride
  • difenoxin hydrochloride
  • difenoxin hydrochloride
  • difenoxin hydrochloride
  • difenoxin hydrochloride, 14c-labeled
  • difenoxinum
  • difenoxinum
  • difenoxylic acid
  • diphenoxilic acid
  • diphenoxilic acid
  • diphenoxin
  • diphenoxin
  • diphenoxylic acid
  • diphenoxylic acid
  • diphenoxylic acid
  • diphenoxylic acid
  • lyspafen
  • mcn-jr-15,403-11
  • mcn-jr-15,403-11
  • motofen
  • motofen
  • r-15403
  • r-15403
  • r-15403 [as hydrochloride]
  • r-15403 [as hydrochloride]

Organizations

Marketing (3)

OrganizationOrg typeRelationshipDate
LEGACY PHARMAFor profitNDA2Jul 14, 1978
Sebela PharmaceuticalsFor profitNDA2Jul 14, 1978
Sebela PharmaceuticalsFor profitNDAJul 14, 1978